Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes

NCT03015220 · Completed

Last updated 2026-05-28

This clinical trial is testing the safety of two diabetes medications, oral semaglutide and dulaglutide, when taken with one other diabetes drug in adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 458 people

Who can join Ages 20+ · all sexes

Timeline Started 2017-01 · est. completion 2018-07

Where 34 sites · Japan

What this study is testing ClinicalTrials.gov NCT03015220 ↗

Description as written by the study sponsor.

This trial is conducted in Asia. The aim of this trial is to investigate Safety and efficacy of oral semaglutide versus dulaglutide both in combination with one OAD (oral antidiabetic drug) in Japanese subjects with type 2 diabetes.

Treatments tested

Semaglutide Drug

Oral administration once-daily, as add-on to pre-trial oral antidiabetic drug (OAD).
Dulaglutide Drug

Subcutaneously administration (s.c., under the skin) once-weekly, as add-on to pre-trial oral antidiabetic drug (OAD).

Main thing measured	Number of Treatment-emergent Adverse Events (TEAEs)
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	semaglutide, dulaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03015220 ↗